A groundbreaking review, recently published in the Chinese Medical Journal on August 8, 2025, sheds illuminating light on the multifaceted immune evasion strategies employed by CTCs during their circulation. Spearheaded by Xiaowei Liu and colleagues at the Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, this article delves into the dynamic crosstalk between CTCs and the host immune system. It underscores how CTCs manipulate their microenvironment to escape immune eradication, thus propelling metastatic dissemination.

CTCs do not circulate as isolated entities. Instead, they intricately engage with diverse blood components—including platelets, natural killer (NK) cells, T lymphocytes, neutrophils, macrophages, myeloid-derived suppressor cells (MDSCs), and endothelial cells—to sculpt a niche favorable for their persistence. Platelets, in particular, cloak CTCs, shielding them from cytotoxic immune cells and facilitating endothelial adhesion at distant sites. This cellular entourage not only camouflages CTCs but actively modulates immune signaling pathways, fostering a microenvironment conducive to metastasis.

At the molecular frontier, CTCs deploy an arsenal of immune checkpoint ligands such as programmed death-ligand 1 (PD-L1), cluster of differentiation 47 (CD47), and human leukocyte antigen-E (HLA-E). These molecules interact with receptors on immune effector cells, effectively silencing cytotoxic responses. Concurrently, CTCs downregulate classical major histocompatibility complex class I (MHC-I) molecules, impairing antigen presentation and thwarting recognition by cytotoxic T cells. This dual modulation profoundly compromises immune detection and elimination.

A notable immune escape mechanism involves resistance to Fas-mediated apoptosis, a pathway typically activated when immune cells engage potential targets. By circumventing this apoptotic trigger, CTCs enhance their survival odds within the circulation. Furthermore, the formation of multicellular clusters—aggregates of CTCs often bound together with platelets or immune cells—provides a physical barrier against immune assault and mechanical stress. These clusters exhibit heightened metastatic potential compared to single CTCs, as they resist anoikis, the programmed cell death induced by detachment from the extracellular matrix.

Intriguingly, endocytosis of platelets by CTCs enables acquisition of platelet-derived proteins and transcripts, further amplifying their immune-evasive properties. This phenomenon bestows CTCs with a dynamic repertoire of immune-modulating factors, effectively cloaking them in ‘self’ signals that deter immune-mediated clearance. Simultaneously, interactions with neutrophils can lead to the formation of neutrophil extracellular traps (NETs), which paradoxically may aid in CTC arrest and subsequent extravasation into target organs.

The review emphasizes the potential clinical implications of these insights. Targeting platelet-CTC interactions through anti-platelet therapies could unmask CTCs to immune recognition, enabling their clearance. Likewise, immune checkpoint inhibitors—currently revolutionary in cancer therapy—emerge as promising agents to disrupt CTC immune evasion. Molecular targeted therapies aimed at modulating MHC expression or blocking survival pathways activated in CTCs present additional therapeutic avenues. Moreover, agents disrupting CTC clusters could reduce metastatic efficiency, offering a novel strategy in curtailing cancer spread.

Beyond therapeutic prospects, the evolving understanding of CTC biology positions these cells as valuable biomarkers in liquid biopsy. Their dynamic molecular profiles provide real-time insights into tumor evolution, treatment resistance, and metastatic potential. By integrating CTC analysis into clinical workflows, oncologists can refine prognostication and personalize therapy, improving patient outcomes.

This comprehensive exploration into the interplay between CTCs and the immune system enriches our understanding of metastasis, historically one of the most enigmatic and lethal facets of cancer. The findings highlight an intricate dance of immune suppression, cellular alliances, and molecular subterfuge by CTCs, underscoring the complexity of metastatic colonization. As researchers continue to unravel these mechanisms, the prospect of translating this knowledge into effective anti-metastatic interventions becomes increasingly tangible.

Xiaowei Liu and the research team’s contribution marks a significant leap in oncology, bridging mechanistic insights with clinical relevance. Their elucidation of the immune strategies employed by CTCs paves the way for innovative treatments that could ultimately thwart the metastatic cascade, transforming cancer from a fatal disease into a manageable condition.

Future research inspired by this review is poised to delve deeper into the molecular dialogues between CTCs and immune and blood cells, aiming to identify novel targets and biomarkers. Such work promises to accelerate the development of therapies that dismantle the protective niches CTCs construct, restoring the efficacy of immune surveillance and preventing the lethal spread of cancer.

In the relentless battle against cancer, understanding the microenvironmental crosstalk and immune evasion tactics of circulating tumor cells offers a beacon of hope. As science advances, targeting these elusive cells could herald a new era in oncology—one where metastasis is no longer a death sentence but a condition amenable to precise and effective intervention.

Subject of Research: Cells

Article Title: Microenvironment crosstalk and immune evasion of circulating tumor cells: From mechanism to clinical significance

News Publication Date: 8-Aug-2025

Web References: DOI 10.1097/CM9.0000000000003738

Image Credits: Xiaowei Liu from Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China

Keywords: Health and medicine, Cell biology, Life sciences, Tumor cells, Diseases and disorders, Cancer research, Clinical research, Medical treatments, Cancer treatments, Cancer immunotherapy, Immune system, Immunology, Adaptive immune system

Colorectal cancer remains one of the leading causes of cancer mortality worldwide, largely due to its propensity for metastasis. EMT, a process originally characterized in embryonic development, allows epithelial cells to acquire mesenchymal properties, facilitating detachment and invasion into surrounding tissues. Understanding the molecular switches that control EMT in CRC has been a paramount objective in cancer biology, with hopes of unveiling novel therapeutic targets.

This comprehensive investigation employed multi-omics bioinformatics analyses encompassing vast transcriptomic datasets derived from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). By rigorously mining these datasets, the researchers identified a panel of 36 differentially expressed genes closely tied to the EMT process in CRC samples. These genes were entrenched in critical signaling cascades including extracellular matrix (ECM)-receptor interaction, focal adhesion, and the PI3K-Akt pathway, pathways notorious for their roles in cancer cell survival and motility.

To distill the most impactful prognostic biomarkers among the EMT-related genes, the team leveraged sophisticated machine learning techniques, particularly the random survival forest (RSF) model. This approach excelled in stratifying CRC patients into distinct risk categories with significant differences in overall survival outcomes. Among the candidates, COMP emerged as a standout hub gene, demonstrating strong statistical association with poor patient prognosis.

Delving deeper into COMP’s mechanistic roles, single-cell RNA sequencing analyses revealed its enriched expression in specific cell populations within CRC tissues, underpinning its selective involvement in tumor progression. Clinical validation using colorectal cancer tissue samples further substantiated these findings. High COMP expression levels correlated with disrupted EMT marker balances, notably an upregulation of mesenchymal markers and suppression of adherent epithelial markers such as E-cadherin, hallmark features of aggressive, invasive tumors.

In vitro experiments using HT-29 colorectal cancer cells painted a compelling picture of COMP’s functional influence. Knockdown of COMP led to a marked restoration of epithelial characteristics, underscoring a reversal of EMT. Concomitantly, there was a significant reduction in cellular proliferation, invasion, and migratory capacities, coupled with enhanced apoptotic activity. These observations underscore COMP’s role not only as a biomarker but also as a functional driver of malignant phenotypes in CRC.

The study’s integrative strategy, combining big data analytics with molecular biology and clinical validation, represents a paradigm shift in how oncogenic pathways can be deciphered and exploited. By mapping COMP within ECM-receptor interactions and PI3K-Akt signaling, researchers highlighted its critical positioning at the crossroads of pathways that confer cellular plasticity and survival advantage to tumor cells.

Notably, the link between COMP and ECM remodeling elucidates a vital aspect of the tumor microenvironment’s contribution to cancer dissemination. The ECM is a dynamic scaffold that, when altered, facilitates invasive behavior. COMP appears to modulate this niche, thereby enhancing the metastatic potential of colorectal cancer cells.

This discovery holds profound implications for clinical management. COMP expression could serve as a prognostic indicator to identify high-risk CRC patients who might benefit from more aggressive or targeted therapeutic regimens. Furthermore, therapeutic strategies aimed at inhibiting COMP function may arrest the EMT process, impeding metastasis and improving patient outcomes.

The revelation of COMP’s critical role also invites exploration into combinatory treatments. Targeting COMP alongside PI3K-Akt inhibitors may provide synergistic suppression of CRC progression, addressing resistance mechanisms commonly encountered with monotherapies.

Beyond its immediate translational relevance, the study brings attention to the power of machine learning in oncology research. By adopting the RSF model, the team effectively navigated high-dimensional genomic data to pinpoint clinically significant molecular markers, exemplifying the future trajectory of precision medicine.

Importantly, the findings call for further functional studies to elucidate the downstream signaling events governed by COMP, as well as its interplay with other components of the tumor microenvironment. Understanding these nuances could pave the way for novel interventions that disrupt metastatic cascades at multiple levels.

In a disease where metastasis drastically diminishes survival rates, identifying molecular gatekeepers like COMP offers a beacon of hope. This research not only deepens scientific comprehension of CRC biology but also charts a course towards targeted interventions, potentially reducing morbidity and mortality associated with late-stage colorectal cancer.

As cancer researchers worldwide grapple with the heterogeneous and adaptive nature of tumors, discoveries such as COMP’s role in EMT underscore the necessity of interdisciplinary approaches—melding computational power, molecular insight, and clinical acumen—to outpace cancer’s advancement.

Ultimately, this study propels the field forward by linking molecular intricacies with tangible clinical challenges, embodying the promise of translational oncology. COMP stands as a testament to the dynamic interplay between tumor cells and their microenvironment, orchestrating the deadly symphony of colorectal cancer metastasis.

Subject of Research: Colorectal cancer progression and metastasis through epithelial-mesenchymal transition
Article Title: COMP promotes the progression of colorectal cancer by regulating epithelial mesenchymal transition
Article References: Huang, H., Wang, L., Gao, S. et al. COMP promotes the progression of colorectal cancer by regulating epithelial mesenchymal transition. BMC Cancer 25, 1710 (2025). https://doi.org/10.1186/s12885-025-15000-3
Image Credits: Scienmag.com
DOI: 10.1186/s12885-025-15000-3